Ophthalmology News

Ophthal

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Habot-Wilner Z et al. - Topically administered bevacizumab at a concentration of 4 mg/ml significantly reduces corneal NV according to both clinical and histopathological evaluations; lower concentrations were less effective on both parameters.

Related Articles

Donor Risk Factors for Graft Failure in the Cornea Donor Study
Cornea, 10/14/09    Relevance Score: 91%%

Relation between Axial Length and Ocular Parameters
Ophthalmologica, 10/28/09    Relevance Score: 89%%

Evaluation of Keratometric, Pachymetric, and Elevation Parameters of Keratoconic Corneas With Pentacam
Cornea, 10/14/09    Relevance Score: 89%%

Customized Aspheric Treatment Zone Ablation to Treat Irregular Corneas After Corneal Refractive Surgery
Journal of Refractive Surgery, 10/23/09    Relevance Score: 87%%

In-vivo confocal microscopy reveals cellular-level detail of lymph vessels in live, unlabelled corneas
Investigative Ophthalmology and Visual Science, 10/15/09    Relevance Score: 87%%

Today in Clinical Pharmacology...keeping you current

Pharmacological and environmental factors in primary angle-closure glaucoma
British Medical Bulletin, 11/25/09

Vitreous Nonsteroidal Antiinflammatory Drug Concentrations and Prostaglandin E2 Levels in Vitrectomy Patients Treated With Ketorolac 0.4%, Bromfenac 0.09%, and Nepafenac 0.1%
Retina, 11/25/09

Infliximab and anterior optic neuropathy
Graefe's Archive for Clinical and Experimental Ophthalmology, 11/23/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address